Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.76 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 5/20 | 0.48 |
| ▸ | TNF | P01375 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13085756 | 0.89 | HRH3 (0.74) | HRH3HPGDCYP11B2CYP11B1TNF | |
| SCHEMBL13085918 | 0.89 | HRH3 (0.74) | HRH3HPGDCYP11B2CYP11B1TNF | |
| SCHEMBL2886483 | 0.86 | HRH3 (0.81) | HRH3CYP11B2CYP11B1ALDH1A1IDO1 | |
| SCHEMBL13085882 | 0.80 | HRH3 (0.74) | HRH3HPGDCYP11B2CYP11B1TNF | |
| SCHEMBL2885662 | 0.78 | CYP11B1 (0.67) | HRH3CYP11B2CYP11B1ALDH1A1IDO1 | |
| SCHEMBL2884355 | 0.77 | HRH3 (0.73) | HRH3CYP11B2CYP11B1TNFHDAC1 | |
| SCHEMBL13085854 | 0.77 | HRH3 (0.59) | HRH3HPGDCYP11B2CYP11B1RAB9A | |
| SCHEMBL13920477 | 0.75 | LOXL2 (0.62) | NPC1RAB9ALOXL2 | |
| SCHEMBL13920478 | 0.75 | LOXL2 (0.62) | NPC1RAB9ALOXL2 | |
| SCHEMBL2883495 | 0.75 | HRH3 (1.00) | HRH3HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820825-B2 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH LLC (US) | 2010-10-26 | — | — | US | disclosed |
| US-7820825-B2 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH LLC (US) | 2010-10-26 | — | — | US | disclosed |
| US-20070219240-A1 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH (US) | 2007-09-20 | — | — | US | disclosed |
| US-20070219240-A1 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH (US) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219240-A1 | N-substituted-azacyclylamines as histamine-3 antagonists | HNMT, HRH4, HRH3 | HRH3 3/4885HPGD 508/4885CYP11B2 2197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.